YinN, ShermanSI, PakY, LitofskyD, GianoukakisA. 2020. The de novo detection of anti-thyroglobulin antibodies and differentiated thyroid cancer recurrence. Thyroid, 30:1490–1495.
2.
CôrtesMCS, RosarioPW, OliveiraLFF, CalsolariMR. 2018. Clinical impact of detectable antithyroglobulin antibodies below the reference limit (borderline) in patients with papillary thyroid carcinoma with undetectable serum thyroglobulin and normal neck ultrasonography after ablation: a prospective study. Thyroid, 28:229–235.
3.
CarvalhoMS, RosarioPW, MourãoGF, CalsolariMR. 2017. Chronic lymphocytic thyroiditis does not influence the risk of recurrence in patients with papillary thyroid carcinoma and excellent response to initial therapy. Endocrine, 55:954–958.
4.
FatemiS, LoPrestiJ, DlottR, PetrovicI, SpencerCA. 2019. High DTC recurrence and mortality for patients with de novo appearance or re appearance of thyroglobulin autoantibodies (TgAb) during long term follow-up. Thyroid, 29(Suppl 1):A87.
5.
HaugenBR, AlexanderEK, BibleKC, DohertyGM, MandelSJ, NikiforovYE, PaciniF, RandolphGW, SawkaAM, SchlumbergerM, SchuffKG, ShermanSI, SosaJA, StewardDL, TuttleRM, WartofskyL. 2016. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid, 26:1–133.
6.
RosarioPW, CarvalhoM, MourãoGF, CalsolariMR. 2016. Comparison of antithyroglobulin antibody concentrations before and after ablation with 131I as a predictor of structural disease in differentiated thyroid carcinoma patients with undetectable basal thyroglobulin and negative neck ultrasonography. Thyroid, 26:525–531.
